BioNTech's coronavirus portfolio isn't doing as well as last year. The company has a rich pipeline, but few of its products are in late-stage studies. Still, like many other vaccine makers that made a ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...
As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 ...
BioNTech SE's $11.1bn BMS deal for BNT-327 highlights promise in PD-L1/VEGF oncology, but clinical validation is still needed. Despite strong COVID vaccine cash flow, BioNTech's share price stagnates ...
Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its ...
BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines. The company has acquired MediLink Therapeutics' ADC technology and ...
MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback